EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells
about
The epidermal growth factor receptor variant III (EGFRvIII): where wild things are alteredAnti-tumor activity of an immunotoxin (TGFα-PE38) delivered by attenuated Salmonella typhimuriumEpidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neckImmunological treatment options for locoregionally advanced head and neck squamous cell carcinomaConvection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1.Innovative Therapies against Human Glioblastoma MultiformeA bivalent recombinant immunotoxin with high potency against tumors with EGFR and EGFRvIII expression.Combating immunosuppression in gliomaTumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.EGF receptor variant III as a target antigen for tumor immunotherapy.Genetically engineered T cells to target EGFRvIII expressing glioblastoma.The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patientsChallenges in clinical design of immunotherapy trials for malignant glioma.Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial.Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.
P2860
Q27015045-11C4393D-8206-4390-8A1A-1D6B5411572FQ33914020-AE56E382-2DBA-450C-ADC2-85CEAFCAA4EAQ34159125-FB4C42D2-D27A-46B6-8C94-A2691FE293CFQ34181954-B9634DC7-EABB-4B1C-A7D0-0C9C8A878970Q34856189-8A4B8FA5-27AB-4A26-AC49-C54915914F62Q35374492-C98661AB-4555-4C44-B3D9-26671ED21336Q36843748-5ED15BDF-361A-47AD-B6B4-C08A8057CE70Q37179415-A61A54C3-99C8-4674-8ACE-535AC443745EQ37186248-D8041F0C-A124-4D2E-B42D-AE82CDE107D4Q37259602-C6134D18-40F7-494E-9316-5E4FA81F1408Q37316117-92290D4E-3418-4E33-ABFA-79A0FA7D580CQ37475929-B9EF86B6-F7F5-4C87-9097-5547D7F10702Q37640613-FE11BD5B-B93D-471D-A9B5-327B725F57D9Q38724406-F2042D11-CB8F-4653-AEC4-AAFF84B7B242Q41022992-3F8F4BAA-42BE-4079-BD14-A6AA514A3FD9
P2860
EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
EGFRvIII-targeted immunotoxin ...... sence of CD4+ and CD8+ T cells
@ast
EGFRvIII-targeted immunotoxin ...... sence of CD4+ and CD8+ T cells
@en
type
label
EGFRvIII-targeted immunotoxin ...... sence of CD4+ and CD8+ T cells
@ast
EGFRvIII-targeted immunotoxin ...... sence of CD4+ and CD8+ T cells
@en
prefLabel
EGFRvIII-targeted immunotoxin ...... sence of CD4+ and CD8+ T cells
@ast
EGFRvIII-targeted immunotoxin ...... sence of CD4+ and CD8+ T cells
@en
P2093
P2860
P1476
EGFRvIII-targeted immunotoxin ...... sence of CD4+ and CD8+ T cells
@en
P2093
Chien-Tsun Kuan
Duane A Mitchell
Gary E Archer
Hidenobu Ochiai
Ira H Pastan
James E Herndon
John H Sampson
P2860
P2888
P304
P356
10.1007/S00262-007-0363-7
P577
2007-07-19T00:00:00Z
P5875
P6179
1007170979